Sunday, November 11 |
|
| 7:45 am - 8:30 am | Registration Open |
| 8:00 am - 8:05 am | Announcements Robert Zimmerman, SD Bayer Pharmaceutical Division |
| 8:05 am - 11:10 am | New Agents in Development Co-Chairs: Ronald Bukowski, MD Cleveland Clinic Alexander Eggermont, MD, PhD |
| 8:05 am - 8:30 am | Thalidomide and its Successor Molecules
as Agents for Biological Therapy Jerry Zeldis, MD, PhD Celgene Corporation |
| 8:30 am - 8:55 am | From Coley’s Toxins to CpG DNA:
Immunotherapy with CpG Motifs From Bacterial DNA Arthur M. Krieg, MD Coley Pharmaceutical Group |
| 8:55 am - 9:20 am | Supression of BCL-2 Gene Expression
by Targeted Disruption of RNA Burkhard Jansen, MD University of Vienna |
| 9:20 am - 9:40 am | Break |
| 9:40 am - 9:55 am | ANGIOZYME, a Synthetic Ribozyme Targeting
the mRNA of VEGFR-1:Clinical Update David Wang, MD, PhD Cleveland Clinic |
| 9:55 am - 10:10 am | Pharmacokinetics in Beagle Dogs and
Cynomologus Monkeys, of VNP20009, an Attenuated Salmonella
Typhimurium for the Treatment of Cancer Caroline Clairmont, PhD Vion Pharmaceuticals, Inc. |
| 10:10 am - 10:25 am | A Phase 2 Trial To Evaluate
the Rate of Immune Response Using Recombinant Idiotype
for Treatment of Follicular Non- Hodgkin’s Lymphoma
Lori Kunkel, MD Genitope Corporation |
| 10:25 am - 10:40 am | Shikonin, a Small Molecule
Compound from Chinese Herbal Medicine with Anti- inflammatory
and Anti-HIV-1 Activity, is an Inhibitor of Multiple Chemokine
Receptors Xin Chen, MD, PhD Center for Cancer Research National Cancer Institute |
| 10:40 am - 10:55 am | TRAIL Induced Apoptosis of Human Melanoma
is Regulated by Smac/DIABLO Release from Mitochondria
Peter Hersey MD, PhD Royal Newcastle Hospital |
| 10:55 am - 11:10 am | The Proteasome Inhibitor PS-341 Sensitizes
Tumor Cells to TRAIL-mediated Lysis Thomas J. Sayers, PhD Center for Cancer Research National Cancer Institute |
| 11:10 am - 11:25 am | Closing Comments Robert O. Dillman, MD President, SBT |
